Why Pfizer's Turnaround Looks Real — A Tactical Long on PFE
Pfizer appears to be moving past the COVID-era revenue cycle and into a steadier, higher-margin growth phase driven by new product rollouts, cost discipline, and recurring vaccine demand. This trade idea lays out an actionable long with entry, stop, and target prices and a clear risk framework.